Method of treating hepatitis virus infections
AssigneesWake Forest University, The University of North Carolina at Chapel Hill
InventorsSusan L. Morris-Natschke, Louis S. Kucera
Life of this patent
Estimating the term…
Abstract
A method of treating hepatitis virus infection is disclosed. The method comprising administering to a human subject in need of such treatment an effective hepatitis virus-combatting amount of an alkyl lipid or alkyl lipid derivative.
Claims44
A method of inhibiting the production of hepatitis virus-induced antigens in a human subject, said method comprising administering an antigen inhibiting amount of a compound of Formula I:
- ##STR7## wherein Y is S, O, NH, NCH.sub.3, NHC(O), or NCH.sub.3 C(O);
- R.sub.1 is unbranched or branched, saturated or unsaturated C1-C20 alkyl, alkenyl, or alkynyl;
- X is a covalent bond or methylene optionally substituted with hydroxyl, C1-C20 alkyl, C1-C20 alkoxy, C1-C20 alkylthio or C1-C20 alkylamido;
- and D is selected from the group consisting of Formula V and Formula VI;
- wherein Formula V is
- --(PO.sub.4).sup.- --E (V)
- wherein E is selected from the group consisting of:
- --J--N.sup.+ (R.sub.2)(R.sub.3)(R.sub.4),
- wherein J is C1-C4 alkyl optionally substituted one to three times with methyl or ethyl;
- and R.sub.2, R.sub.3, and R.sub.4 are independently selected from the group consisting of H and C1-C3 alkyl;
- and
- a nucleic acid base conjugate of the Formula VII ##STR8## wherein the base is selected from the group consisting of thymine, adenine, cytosine, guaninie, hypoxanthine, uracil, 2'-3'-dideoxy-3'-thiacytidine, and 2-aminoadenine;
- A is H, fluorine, or N.sub.3 ;
- and B is H or fluorine, or A and B together form a covalent bond;
- and wherein Formula VI is
- --N.sup.+ (R.sub.5)(R.sub.6)--J--W Z.sup.- (VI)
- wherein R.sub.5 and R.sub.6 are independently selected from the group consisting of H and C1-C3 alkyl;
- J is as defined above;
- W is --OH, or --SH;
- and
- Z.sup.- is an anion;
- or a pharmaceutical salt thereof.
A method of inhibiting the production of hepatitis virus-induced antigens in a human subject, said method comprising administering an antigen-inhibiting amount of a compound of Formula II:
- ##STR9## wherein Y is S, O, NH, NCH.sub.3, NHC(O), or NCH.sub.3 C(O);
- R.sub.1 is an unbranched or branched, saturated or unsaturated C1-C20 alkyl, alkenyl, or alkynyl;
- X is a covalent bond or methylene optionally substituted with hydroxyl, C1-C20 alkyl, C1-C20 alkoxy, C1-C20 alkylthio or C1-C20 alkylamido;
- J is C.sub.1 -C.sub.4 alkyl optionally substituted 1 to 3 times with methyl or ethyl, and R.sub.2, R.sub.3 and R.sub.4 are independently selected from the group consisting of H and C1-C3 alkyl, or a pharmaceutical salt thereof.
A method of inhibiting the production of hepatitis virus-induced antigens in a human subject, said method comprising administering an antigen inhibiting amount of a compound of Formula III:
- ##STR10## wherein Y is S, O, NH, NCH.sub.3, NHC(O), or NCH.sub.3 C(O);
- R.sub.1 is an unbranched or branched, saturated or unsaturated C1-C20 alkyl, alkenyl, or alkynyl;
- X is a covalent bond or methylenie optionally substituted 1 or 2 times with hydroxyl, C1-C20 alkyl, C1-C20 alkoxy, C1-C20 alkylthio or C1-C20 alkylamido;
- J is C1-C.sub.4 alkyl optionally substituted 1 to 3 times with methyl or ethyl;
- R.sub.2 and R.sub.3 are independently selected from the group consisting of H and C1-C3 alkyl;
- and W is --OH or --SH.
A method of inhibiting the production of hepatitis virus-induced antigens in a human subject, said method comprising administering an antigen inhibiting amount of a compound of Formula IV:
- ##STR11## wherein Y is S, O, NH, NCH.sub.3, NHC(O), or NCH.sub.3 C(O);
- R.sub.1 is an unbranched or branched, saturated or unsaturated C1-C20 alkyl, alkenyl, or alkynyl;
- X is a covalent bond or methylene optionally substituted with hydroxyl, C1-C20 alkyl, C1-C20 alkoxy, C1-C20 alkyltlio or C1-C20 alkylamido;
- Base is selected from the group consisting of thymine, adenine, cytosine, guanine, hypoxanthine, uracil, 2'-3'-dideoxy-3'-thiacytidirie and 2-aminoadenine;
- A is H, fluorine, or N.sub.3 ;
- and B is H or fluorine or A and B together form a covalent bond.
Dependencies are inferred from the claim text.